Fuente: PubMed "Cannabis" Rev Med Interne. 2026 Jul 10:S0248-8663(26)00638-7. doi: 10.1016/j.revmed.2026.06.013. Online ahead of print.ABSTRACTCannabis has been used for nearly five millennia for its medicinal properties. The endocannabinoid system and the pharmacology of the main phytocannabinoids (Δ9-tetrahydrocannabinol, cannabidiol) were characterized between the 1970s and 1990s. Two types of cannabinoid receptors have been identified: type 1 receptors, primarily located in the central and peripheral nervous systems, and type 2 receptors, expressed notably by immune cells and the spleen (type 2). The development of cannabinoid-derived drugs, such as dronabinol, nabiximols, and cannabidiol, is based on two main principles: their role in modulating the release of presynaptic neurotransmitters and their anti-inflammatory and analgesic effects, demonstrated in experimental models and in humans. These treatments are currently used primarily for the symptomatic management of spasticity associated with multiple sclerosis, neuropathic pain, and epilepsy. From an immunological perspective, cannabinoids exert complex effects, including inhibition of CD4+ T-cell and B-cell proliferation, as well as a shift toward a Th2 profile, associated with reduced production of pro-inflammatory cytokines. However, clinical studies evaluating their effects in autoimmune diseases remain scarce. The available, heterogeneous data underscore the need for further basic and clinical research to better characterize these mechanisms and their therapeutic implications.PMID:42431734 | DOI:10.1016/j.revmed.2026.06.013